标题
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
作者
关键词
-
出版物
Therapeutic Advances in Chronic Disease
Volume 9, Issue 1, Pages 5-21
出版商
SAGE Publications
发表日期
2017-11-16
DOI
10.1177/2040622317738910
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
- (2017) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
- (2017) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial
- (2017) J.-P. Lacour et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
- (2017) Iain B McInnes et al. RHEUMATOLOGY
- Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
- (2017) Arthur Kavanaugh et al. ARTHRITIS CARE & RESEARCH
- Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis
- (2016) Ju Yeon Ryoo et al. ANNALS OF PHARMACOTHERAPY
- THU0437 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Licensed Biologics and Apremilast from A Network Meta-Analysis
- (2016) I.B. McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
- (2016) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA
- (2016) N. J. Korman et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
- (2016) Neil J. Korman et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
- (2016) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
- (2016) A. Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis
- (2016) Patompong Ungprasert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial
- (2015) M. Augustin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
- (2014) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
- (2014) Charles W. Lynde et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice
- (2013) K. Callis Duffin et al. BRITISH JOURNAL OF DERMATOLOGY
- Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis
- (2012) Senem Buyukkara Yilmaz et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
- (2012) P. Rich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
- (2012) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities
- (2011) Sue Ann Chan et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2011) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Maximizing patient adherence for optimal outcomes in psoriasis
- (2011) A Bewley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.
- (2010) K Abuabara et al. BRITISH JOURNAL OF DERMATOLOGY
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
- (2010) Andrea Chiricozzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
- (2010) Pieter C. M. Res et al. PLoS One
- Serum cytokines and growth factor levels in Japanese patients with psoriasis
- (2009) H. Takahashi et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
- (2009) Erin G. Harper et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
- (2008) Michelle A. Lowes et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started